- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.11. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 September 2025 | 49 | GlobeNewswire (Europe) | Third quarter (July-September 2025)
Operating loss amounted to SEK 146,689 (-2,697,267).
Loss for the period amounted to SEK 304,153 (-2,514,629).
Cash flow from operating activities totaled SEK... ► Artikel lesen | |
| 13.11. | Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research | 1 | Cision News | ||
| 23.10. | Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ) | 2 | Cision News | ||
| 19.09. | ELICERA THERAPEUTICS: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 2 | Cision News | ||
| 19.09. | Elicera Therapeutics AB: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 132 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 29.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 June 2025 | 165 | GlobeNewswire (Europe) | Second quarter (April-June 2025)
Operating loss amounted to SEK -2,892,341 (-5,841,409).
Loss for the period amounted to SEK -2,732,070 (-5,622,779).
Cash flow from operating activities totaled... ► Artikel lesen | |
| 25.08. | ELICERA THERAPEUTICS: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 2 | Cision News | ||
| 25.08. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 125 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 25.08. | Elicera Therapeutics AB: Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee's Assessment in Cohort 2 | 136 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 28.05. | Elicera Therapeutics AB: Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201 | 176 | GlobeNewswire (Europe) | Gothenburg, May 28, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 22.05. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy | 173 | GlobeNewswire (Europe) | Gothenburg, May 22, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 15.05. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 31 March 2025 | 174 | GlobeNewswire (Europe) | First quarter (January-March 2025)
Operating loss amounted to SEK -8,069,404 (-5,433,422).
Loss for the period amounted to SEK -8,013,462 (-5,369,677).
Cash flow from operating activities totalled... ► Artikel lesen | |
| 10.04. | Elicera Therapeutics AB: Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1 | 332 | GlobeNewswire (Europe) | Gothenburg, April 10, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 376 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 172 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen | |
| 28.11.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2024 | 126 | GlobeNewswire (Europe) | Third quarter (July-September 2024)
Operating profit/loss amounted to SEK -2,697,267 (-5,149,440).
Loss for the period amounted to SEK -2,514,629 (-5,046,574).
Cash flow from operating activities... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,206 | +0,58 % | Evotec: Startet jetzt der Turnaround? | ||
| REGENERON PHARMACEUTICALS | 656,60 | +0,06 % | Dividendenbekanntmachungen (20.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLIENT INC US0193301092 0,03 USD 0,0259 EUR APPLIED MATERIALS INC US0382221051 0,46 USD 0,3986 EUR APPLIED MATERIALS INC CDR CA03822G1046 0... ► Artikel lesen | |
| BRAIN BIOTECH | 3,650 | +2,53 % | BRAIN BIOTECH AG explodiert - jetzt bloß nicht zögern! | ||
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| CARDIOL THERAPEUTICS | 0,830 | -1,78 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 | Once issued, this new U.S. patent covers the use of CardiolRx and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,160 | +4,50 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 Second Quarter Results | Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CSL | 100,66 | -0,08 % | Neue Location, gleiche Mission: Eröffnung eines CSL Plasma Centers im ehemaligen 'Knutschfleck' | Berlin (ots) - In der Alexanderstraße 3 gibt es ab sofort eine neue Anlaufstelle für Plasmaspender: CSL Plasma hat heute feierlich die neuen Räumlichkeiten am Alexanderplatz, die früher zu dem für Varieté... ► Artikel lesen | |
| MANNKIND | 4,321 | -1,17 % | MannKind: Stiller Gewinner im Kampf um die Lunge? | Nach einer Reihe operativer Fortschritte und der Übernahme von scPharmaceuticals richtet sich bei Aktionären der MannKind Corporation der Blick in die Zukunft. Die fundamentale Basis scheint geschaffen.... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,490 | -1,27 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Third Quarter 2025 Financial Results and Business Highlights | Recent Investor Day highlighted how AXPAXLI is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,536 | +1,05 % | Oxford Nanopore Technologies: ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology | New adventitious viral agent (AVA) detection test offers rapid, sensitive, and affordable viral screening for biomanufacturers
ViruSure, a global leader in pathogen safety testing for biopharmaceuticals... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,052 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 1,385 | +3,20 % | Codexis, Inc.: Codexis Reports Third Quarter 2025 Financial Results | Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif.,... ► Artikel lesen | |
| CORMEDIX | 8,100 | -3,57 % | H.C. Wainwright Raises the PT on CorMedix Inc. (CRMD), Keeps a Buy | ||
| TELO GENOMICS | 0,032 | -3,08 % | Telo Genomics Corp.: Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025 | Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its proprietary... ► Artikel lesen | |
| BIORA THERAPEUTICS | 0,001 | -100,00 % | NSE - BIORA THERAPEUTICS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,487 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.